Prasinezumab

Prasinezumab (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names NEOD002, PRX-002, RG-7935, RO-7046015) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which is under development for the treatment of Parkinson's disease.^[1][2][3][4] No significant effect on disease progression was seen in a 52-week phase 2 clinical trial.^[2] In any case, the trial was extended and development of the drug continues.^[2] There have been concerns about research misconduct and data fabrication relevant to prasinezumab.^[5] As of May 2024, prasinezumab is in phase 2 clinical trials for Parkinson's disease.^[1] It is under development by Prothena Biosciences and Roche.^[1]

Prasinezumab

Monoclonal antibody
Type	?
Target	α-Synuclein
Clinical data
Other names	NEOD002; NEOD-002; PRX002; PRX-002; RG7935; RG-7935; RO7046015; RO-7046015
Identifiers
CAS Number	1960462-19-4
DrugBank	DB14788
UNII	P3Z0Z3P1ZI

See also

• Cinpanemab